2014
The Impact of Biobanks and Fit-for-Purpose Biospecimens on Precision Medicine (NEW!)
with Carolyn Compton, M.D., Ph.D., CMO, National Biomarkers Development Alliance; CMO, Complex Adaptive Systems Institute; Adjunct Professor, Pathology, Mayo Medical School; Professor, School of Life Sciences, Arizona State University
An-Dinh Nguyen interviews Dr. Compton on July 23, 2014. She will be a plenary keynote speaker at the Leaders in Biobanking Congress and Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change event, September 15-17 in Seattle, WA.
Topics include effects of pre-analytical variables on human biospecimens during acquisition and processing, the importance of fit-for-purpose samples and how biobanks play a role in making personalized cancer therapies possible.
Precise Cancer Surgeries and Drug Treatments: Tumor Paint, Peptides and PDX Models (NEW!)
with James M. Olson, M.D., Ph.D., Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor, Pediatric Hematology and Oncology, University of Washington; Attending Physician, Seattle Children’s Hospital; Founder, Presage Biosciences and Blaze Bioscience
An-Dinh Nguyen interviews Dr. Olson on July 18, 2014. He will be a plenary keynote speaker at the Leaders in Biobanking Congress and Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change event, September 15-17 in Seattle, WA.
Topics include the scorpion venom-derived molecular imaging agent Tumor Paint and its potential applications for cancer treatment, optide therapeutics, drug research and development breakthroughs in pediatric brain tumors through PDX models and more.
Clinical Applications of NGS Gene Panels for Cancer Risk Assessment and Precision Therapy (NEW!)
with Colin C. Pritchard, M.D., Ph.D., Assistant Professor and Associate Director, Genetics and Solid Tumors Laboratory, Laboratory Medicine, University of Washington
An-Dinh Nguyen interviews Dr. Pritchard on July 21, 2014. He will be speaking at Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change, September 15-17 in Seattle, WA.
Topics include clinical applications of next-generation sequencing gene panels for cancer risk assessment and precision treatment, collaborating with Dr. Mary-Claire King, overcoming challenges in translating genetic information into clinical settings, ensuring such data benefit individual patients and more.
The Business of Biobanking: Supporting Clinical Trials and Translational Research (NEW!)
with Stephen Schmechel, M.D., Ph.D., Associate Professor, UW Medicine Pathology and Director, NWBioTrust, University of Washington
An-Dinh Nguyen interviews Dr. Schmechel on July 17, 2014. He will be a short course instructor for Biobanking Is More than Sample Storage and Management and speaker at the Leaders in Biobanking Congress and Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change event, September 15-17 in Seattle, WA.
Topics include critical business considerations for running biobanks to advance personalized medicine, support of translational research and clinical trials through a biobanker/biouser partnership and collaborations between University of Washington, Fred Hutchinson Cancer Research Center, Seattle Children's Hospital and elsewhere.